---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-032974"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:43:39.649463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q4 net loss $29.2M, revenue $14.8M; cash $195.8M plus $325M PIPE

## Summary
- Q4 net loss $29.2M ($0.35 loss per share); revenue $14.8M, up 5% YoY.
- Full year 2023 net loss $80.7M ($1.01 loss per share); revenue $58.4M, up 13.4%.
- Cash $195.8M at year-end; Feb 2024 PIPE added $325M gross proceeds, funding into at least 2028.
- Appointed Pravin Dugel as Executive Chairman and three key retinal care leaders.
- Phase 3 AXPAXLI SOL-1 screening underway; topline data for diabetic retinopathy and PAXTRAVA glaucoma expected Q2 2024.

## SEC filing metadata
- accession: 0001104659-24-032974
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/0001104659-24-032974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/tm248311d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-032974
- JSON: https://secwatch.observer/filing/0001104659-24-032974.json
- Plain text: https://secwatch.observer/filing/0001104659-24-032974.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported the full year ended December 31, 2023 results: revenue $58.4 million.
  - Period: the full year ended December 31, 2023
  - Revenue: $58.4 million
  - Result: reported results
  source text: Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/0001104659-24-032974-index.htm
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported the fourth quarter 2023 results: revenue $14.8 million, net income $(29.2) million, EPS $(0.35) per share on both a basic and diluted basis.
  - Period: the fourth quarter 2023
  - Revenue: $14.8 million
  - Net income: $(29.2) million
  - EPS: $(0.35) per share on both a basic and diluted basis
  - Result: reported results
  source text: Total net revenue was $14.8 million for the fourth quarter of 2023, a 5.0% increase over total net revenue of $14.1 million in the comparable period in 2022, driven by DEXTENZA sales. Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%. Research and development expenses for the fourth quarter of 2023 were $16.2 million versus $13.5 million for the comparable period in 2022, driven primarily by an increase in overall clinical and regulatory expenses associated with product development programs. Overall R&D expenses for the full year increased $7.6 million to $61.1 million from $53.5 million in 2022, reflecting the timing and conduct of our clinical trials. Selling and marketing expenses were $9.2 million in the fourth quarter of 2023, as compared to $10.5 million for the comparable quarter of 2022, primarily reflecting a reduction in personnel costs driven by lower expense for stock-based compensation and other items. Overall, se
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/0001104659-24-032974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.